Q-omics provides the consensus-scored TCP11L1 profile across patient tissues and cancer cell-line models. TCP11L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCP11L1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TCP11L1 protein abundance shows 22,994 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TCP11L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCP11L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCP11L1 survival associations across molecular data types. TCP11L1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCP11L1 RNA expression–survival associations across cancer types. High TCP11L1 expression shows unfavorable associations in MESO, HNSC, KICH, BLCA and ACC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCP11L1 RNA expression.
This table summarizes TCP11L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TCP11L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCP11L1 shows lower tumor expression in COAD and KICH and higher tumor expression in HNSC, KIRC, LIHC and LUSC. The HNSC box plot shows higher TCP11L1 RNA expression in tumor versus normal tissue (log2 FC = +1.415, t-test p < 0.001).
This table shows molecular features associated with TCP11L1 in patient tissues and cancer cell lines. In patient samples, TCP11L1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCP11L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
